Meterone (Medroxyprogesterone Acetate) is relevant across specialized gynecological and oncological domains, focusing on establishing hormonal stability and managing symptoms driven by hormonal activity or imbalance. It is commonly used to help manage symptoms of secondary amenorrhea (absent periods) and abnormal uterine bleeding caused by systemic hormonal imbalances. It is relevant for managing conditions that involve systemic or localized discomfort, such as endometriosis, and is applied in specific contexts like hyperplasia prevention and support for certain hormone-sensitive cancers.

“The goal is to assist in restoring cyclical regularity and contribute to endometrial support for patients requiring hormone therapy.”

Therapeutic Benefits and Clinical Contexts

The medication assists in restoring a more predictable and normal menstrual cycle, helping to ease the discomfort and unpredictability associated with persistent or recurring bleeding patterns. In non-hysterectomized women receiving estrogen, this activity supports endometrial protection, and may assist with lowering the risk of tissue-related complications that may arise from unopposed estrogen therapy. It helps moderate chronic pain associated with endometriosis and is applied in an adjunctive and palliative capacity for cancer support, assisting with symptom clusters that interfere with daily functioning during difficult episodes.

Regulatory References

1. NIH MedlinePlus overview

Meterone (Medroxyprogesterone Acetate) is approved for use in females of reproductive potential, including postmenarchal adolescents. Official regulatory documents define strict criteria for non-eligibility. The medicine is contraindicated in patients with a known or suspected pregnancy and must not be used for diagnosis. It is also prohibited for those with a history of malignancy of the breast or estrogen-dependent neoplasia, active thromboembolic disorders (such as DVT or PE), and significant liver disease. Undiagnosed abnormal genital bleeding must be investigated to rule out malignancy before use.

Use is not indicated before the onset of menstruation (pre-menarche) or for contraception in the geriatric, post-menopausal population. Use is not recommended for a period exceeding two years unless other options are inadequate, due to concerns about bone mineral density (BMD) loss. Special caution or careful surveillance is required for patients with diabetes mellitus or those with pre-existing conditions influenced by fluid retention, such as renal dysfunction or a history of mental depression.

Interactions with other medicines and products

The regulatory interaction profile for Meterone is defined by pharmacokinetic interference, primarily through the CYP3A4 metabolic pathway. Official documentation classifies co-administered medicines based on their ability to alter the systemic exposure of Medroxyprogesterone Acetate (MPA).

The product is formally contraindicated in populations with significant liver disease or impairment, a restriction related to the necessity of normal hepatic clearance for the drug's metabolism. No mandatory timing or separation requirements for co-administration are explicitly documented in the official regulatory summaries. The interaction structure reflects standardized regulatory classifications used to describe enzyme-mediated exposure modification.

Chemical Reduction and Targeted Activation

Meterone is a prodrug that requires chemical activation to become effective. This activation occurs only when the drug encounters specific electron-transport proteins within cells that thrive in low-oxygen environments. This selective chemical process transforms the inactive drug into highly reactive intermediates. This targeted transformation makes the cytotoxic effect dependent on the unique internal cellular environment, directing the action toward susceptible cell populations.

Molecular Disruption of Nucleic Acids

Once activated, the highly potent intermediates rapidly engage the most critical components of the target cell: the DNA and other nucleic acids. This interaction causes structural damage, like strand breaks, which immediately halts the cell's ability to replicate, repair itself, or synthesize necessary proteins. The resulting physiological effect is the destruction and elimination of the targeted cell population from the body.

How Meterone (Medroxyprogesterone Acetate) is Used

Meterone is administered according to specific regimens determined by the route and intended use. The medicine is available in two primary administration methods: oral tablets and parenteral injection (intramuscular and subcutaneous suspensions).

Administration Routes and Schedules

For oral administration, the tablets may be taken with or without food. The short-term oral courses for conditions like secondary amenorrhea are typically repeated over two or three consecutive cycles.

Procedural and Timing Requirements

The injectable suspensions, which are given either deep into the gluteal or deltoid muscle (IM) or into the anterior thigh/abdomen (SC), require specific handling: the suspension must be vigorously shaken just before administration to ensure the dose is uniform.

For long-acting contraceptive use, the standard protocol involves precise timing for the initial dose, which must be given within the first 5 days of a normal menstrual period. If the interval between scheduled injections is missed and exceeds 13 weeks, it is necessary to exclude pregnancy before the next dose is administered. Use of the injectable contraceptive form is generally not recommended for longer than 2 years unless other options are unsuitable.

Research Evidence / Overview of Studies for Meterone

Evidence for Pregnancy Prevention (Contraception)

Research has studied the use of the injectable formulation of Meterone (medroxyprogesterone acetate) as a contraceptive. Studies monitored the incidence of unintended pregnancy over defined time intervals, with clinical trials reporting the calculated effectiveness rates when administered correctly and on schedule. Observational studies have described patterns of use in real-world settings, where continuation rates were tracked across different populations.

In addition to monitoring pregnancy incidence, studies explored the time required for the return of fertility after the medication was stopped. Studies noted that continuous use was associated with observations of changes in bone mineral density (BMD) in some users, particularly in younger women. What remains uncertain is the full extent of BMD recovery after a user discontinues the drug, as long-term effects are not fully established beyond the initial years of observation.

Evidence for Menstrual Cycle Management (Amenorrhea and AUB-O)

Meterone was studied for conditions characterized by fluctuating or episodic manifestations, specifically in research exploring secondary amenorrhea and Abnormal Uterine Bleeding (AUB-O). Research examined different cyclic treatment regimens to see how patterns related to the return of a predictable bleeding pattern were observed. Outcomes related to systemic or functional imbalance were key endpoints.

Studies exploring short-term symptom changes reported that the medication was associated with the observance of cyclical bleeding. Limited information exists from large, placebo-controlled trials focusing purely on cycle regulation after treatment ends, and sample sizes were modest in some comparison trials.

Evidence for Endometrial Protection and Certain Cancers

For endometrial protection in postmenopausal women receiving estrogen therapy, evidence comes from large, long-term randomized trials that examined the drug in combination with estrogen. Findings described patterns observed in the studies where the combined therapy was associated with a different incidence rate of abnormal tissue growth compared to estrogen alone.

For advanced endometrial carcinoma, the drug was studied for its role as an adjunctive or palliative treatment. Studies reported measurements of a certain tumor response rate, which was observed in some studies to be more frequent in patients whose tumors had specific cellular features (e.g., progesterone receptor-positive status). Findings were mixed regarding whether higher doses were associated with a measurable difference in outcomes compared to lower doses.

Key Studies & References

1. Highlights of prescribing information: Depo-Provera CI (medroxyprogesterone acetate) injectable suspension (Contraception, BMD)
2. Women's Health Initiative (WHI) Follow-Up Study: Menopausal Hormone Therapy and Cancer Mortality (Endometrial Protection, Long-term risk)

Common questions about Meterone (FAQ)

Q: Is it safe to use Meterone while breastfeeding?

Official product information indicates that caution should be considered if Meterone (medroxyprogesterone acetate) is administered to a woman who is nursing. This is based on studies that found detectable amounts of the active ingredient in human milk.

Q: How long will it take for my period to return after stopping the injection?

Regulatory documents indicate that the return to fertility and normal ovulation may be temporarily delayed after stopping the injectable form of Meterone. The median time to conception after the last injection has been observed to be several months in clinical studies. This delay is temporary, but it is a known effect of the long-acting injection.

Q: What should I do if I get pregnant while taking Meterone?

Regulatory guidance specifies that Meterone is contraindicated, meaning it should not be used, if you are pregnant or suspect you may be pregnant. The medication must be discontinued immediately. If pregnancy is suspected, it is important to contact a healthcare provider for follow-up and instruction.

Q: Is there an age limit or restriction for using Meterone for contraception?

Official prescribing information states that the injectable form is not indicated for contraception before menarche (the start of menstruation) or in post-menopausal women. Official caution is advised for adolescents and young adults, as use has been associated with a reduction in Bone Mineral Density (BMD) during a critical period of bone growth.

Storage and Disposal Requirements

The storage and disposal profile for Meterone (Medroxyprogesterone Acetate) is defined by official regulatory guidelines to maintain product integrity and ensure safety.

Disposal Instructions

All forms of the medicine must be kept out of the sight and reach of children. Unused or expired medication should be discarded according to local official guidelines or via a drug take-back program. Used needles and syringes from the injectable form must be placed immediately in a designated sharps disposal container.